MNPR Monopar Therapeutics
Price (delayed)
$4.36
Market cap
$15.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$9.23M
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of
Highlights
Monopar Therapeutics's quick ratio has soared by 60% YoY and by 7% from the previous quarter
The EPS has grown by 40% YoY and by 12% from the previous quarter
The equity has contracted by 22% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of MNPR
Market
Valuations
Earnings
Shares outstanding
3.52M
Market cap
$15.35M
Enterprise value
$9.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$7.12M
EBITDA
-$7.12M
Free cash flow
-$6.82M
Per share
Balance sheet
Liquidity
EPS
-$2.3
Free cash flow per share
-$1.95
Book value per share
$1.74
Revenue per share
$0
TBVPS
$2.05
Total assets
$7.18M
Total liabilities
$1.09M
Debt
$0
Equity
$6.09M
Working capital
$6.09M
Debt to equity
0
Current ratio
6.59
Quick ratio
6.53
Net debt/EBITDA
0.86
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-89%
Return on equity
-110.6%
Return on invested capital
N/A
Return on capital employed
-117%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNPR stock price
How has the Monopar Therapeutics stock price performed over time
Intraday
12.95%
1 week
81.67%
1 month
87.12%
1 year
43.89%
YTD
156.47%
QTD
19.45%
Financial performance
How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.49M
Net income
-$7.12M
Gross margin
N/A
Net margin
N/A
The net income has grown by 28% year-on-year and by 6% since the previous quarter
The operating income has grown by 26% YoY and by 7% from the previous quarter
Growth
What is Monopar Therapeutics's growth rate over time
Valuation
What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
2.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 40% YoY and by 12% from the previous quarter
MNPR's price to book (P/B) is 48% more than its last 4 quarters average of 1.5 but 33% less than its 5-year quarterly average of 3.3
The equity has contracted by 22% YoY and by 19% from the previous quarter
Efficiency
How efficient is Monopar Therapeutics business performance
The return on assets has declined by 12% year-on-year and by 2.9% since the previous quarter
MNPR's return on equity is down by 10% year-on-year
Dividends
What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNPR.
Financial health
How did Monopar Therapeutics financials performed over time
The current ratio has surged by 60% year-on-year and by 6% since the previous quarter
Monopar Therapeutics's quick ratio has soared by 60% YoY and by 7% from the previous quarter
The company's debt is 100% lower than its equity
The equity has contracted by 22% YoY and by 19% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.